The Experts below are selected from a list of 198 Experts worldwide ranked by ideXlab platform
Scott A. Halperin - One of the best experts on this subject based on the ideXlab platform.
-
decrease in hospital admissions for febrile seizures and reports of hypotonic hyporesponsive episodes presenting to hospital emergency departments since switching to acellular Pertussis Vaccine in canada a report from impact
Pediatrics, 2003Co-Authors: Nicole Le Saux, Nick Barrowman, Dorothy Moore, Sharon Whiting, David W Scheifele, Scott A. HalperinAbstract:Objective. Acellular Pertussis Vaccines were introduced with the promise of an improved safety profile compared with whole-cell Vaccines. In 1997–1998, Canada adopted 1 combination acellular Pertussis Vaccine, having previously used 1 particular combination whole-cell Pertussis Vaccine. We hypothesized that the change would result in a decrease in hospitalization rates for seizures and reports of hypotonic-hyporesponsive episodes (HHEs) temporally related to Pertussis vaccination. Methods. Active surveillance was performed between 1995 and 2001 by the Immunization Monitoring Program–Active monitors at 12 hospitals using standard case definitions. Seizures had to occur within 72 hours after immunization with a Pertussis-containing Vaccine or 5 to 30 days after immunization with measles-mumps-rubella Vaccine. HHE episodes had to occur within 48 hours of receipt of a Pertussis-containing Vaccine. Poisson regression models were used to compare the average number of monthly admissions for seizures and HHEs before and after introduction of the acellular Pertussis Vaccine. Results. We found a 79% decrease in febrile seizures associated with receipt of Pertussis Vaccine but no significant decrease in febrile seizures temporally related to measles-mumps-rubella between 1995–1996 and 1998–2001. There was a 60% to 67% reduction in HHEs associated with Pertussis-containing Vaccines between the same time periods, depending on case definition. Conclusions. The risks of febrile seizures and HHEs after Pertussis-containing Vaccine declined significantly with the introduction of acellular Pertussis Vaccine in Canada. Active surveillance systems are important for detecting trends in uncommon adverse events after routine immunizations.
-
adverse reactions and antibody response to four doses of acellular or whole cell Pertussis Vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life
Vaccine, 1996Co-Authors: Scott A. Halperin, Luis Barreto, Brian J Eastwood, B Friesen, Lorna Medd, William Meekison, Roland GuaspariniAbstract:To assess the safety, immunogenicity, and lot consistency of a five-component acellular Pertussis Vaccine combined with diphtheria and tetanus toxoid (Connaught Laboratories Limited), we randomly allocated 432 infants to receive one of three lots of an acellular Pertussis Vaccine or a single lot of whole cell Pertussis Vaccine. Infants were immunized at 2, 4 and 6 months of age and between 17 and 19 months of age. Local and systemic adverse reactions were reported significantly more frequently by recipients of the whole cell than acellular Vaccine after each dose. The antibody response against Pertussis toxin, filamentous hemagglutinin, and 69 kDa protein was of greater magnitude in acellular Pertussis Vaccine recipients than whole cell Pertussis Vaccine recipients. Small differences were detected amongst the Vaccine lots tested. We conclude that the acellular Pertussis Vaccine is safe and immunogenic for the first four doses in children under 2 years of age.
-
Acellular Pertussis Vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular Pertussis Vaccine at two, four and six months of age.
The Pediatric infectious disease journal, 1995Co-Authors: Scott A. Halperin, Luis Barreto, Elaine L Mills, Carolyn Pim, Brian EastwoodAbstract:The safety and immunogenicity of two formulations of an acellular Pertussis Vaccine as a booster at 17 to 19 months of age were assessed in children immunized at 2, 4 and 6 months of age with acellular or whole cell Pertussis Vaccine. In Study I 86 children primed with a five-component acellular Vaccine combined with diphtheria and tetanus toxoids or with a whole cell Pertussis-diphtheria-tetanus Vaccine were boosted with the same Vaccine. Local reactions (64% vs. 93% ; relative risk, 0.7 ; 95% confidence interval, 0.5 to 0.9) and systemic reactions (68% vs. 97% ; relative risk, 0.7 ; 95% confidence interval, 0.5 to 0.9) were less common after the fourth dose of acellular Vaccine than after the fourth dose of whole cell Vaccine. In Study II 96 children primed with either an acellular or whole cell Pertussis Vaccine were boosted with an acellular Vaccine. Local adverse reactions after booster immunization with acellular Vaccine were more common in children primed with acellular Vaccine than those primed with whole cell Vaccine (68% vs. 33% ; relative risk, 2.1 ; 95% confidence interval, 1.3 to 3.3). Antibody response to Pertussis toxin, filamentous hemagglutinin and fimbriae were higher before and 1 month after the booster dose in children primed with the acellular Vaccine. We conclude that the acellular Pertussis Vaccine is safe and immunogenic when used for the booster dose in children primed with either whole cell or acellular Vaccine but is associated with local reactions.
Julie Leask - One of the best experts on this subject based on the ideXlab platform.
-
pregnant women s intention to take up a post partum Pertussis Vaccine and their willingness to take up the Vaccine while pregnant a cross sectional survey
Vaccine, 2013Co-Authors: Kerrie E Wiley, Helen E. Quinn, Peter D Massey, Spring Chenoa Cooper, Nicholas Wood, Julie LeaskAbstract:Abstract Introduction Post-partum vaccination of new mothers is currently recommended in Australia to reduce Pertussis infection in infants. Internationally, vaccination recommendations now include pregnant women in some countries. Understanding the awareness of Pertussis vaccination recommendations among pregnant women, and their willingness to have the Vaccine while pregnant is important for informing Vaccine program implementation. Objective To determine awareness and intentions toward current recommendations for post-partum Pertussis vaccination among Australian pregnant women, and their willingness to accept Pertussis Vaccine during pregnancy, should it be recommended in Australia in the future. Design Quantitative self-administered survey, using a non-random stratified sampling plan based on representative proportions by age, parity and region of residence. Participants and setting Pregnant women receiving antenatal care through three large, demographically diverse referral hospitals in metropolitan, urban and rural New South Wales, Australia. Results The response rate was 815/939 (87%). Most women (80%) reported willingness to have the Pertussis Vaccine during pregnancy, should it be recommended. Thirty four per cent of women intended to receive a Pertussis Vaccine post-partum, 17% had received it previously, while 45% had never heard of Pertussis Vaccine, had not thought about it, or were undecided about having it. Compared with those who had not received a recommendation to have the Vaccine post-partum, women who had received a recommendation were 7 times more likely (95% CI 4–14) to report intention to have the Vaccine. Conclusions Health care provider recommendation is paramount to raising awareness of Pertussis vaccination recommendations among pregnant women. Women's willingness to have the Vaccine while pregnant is encouraging, and indicates the potential for high Pertussis Vaccine coverage among pregnant women, should it be recommended in Australia.
Susan J. Keam - One of the best experts on this subject based on the ideXlab platform.
-
Reduced-Antigen, Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine, Adsorbed (Boostrix® US Formulation)
Pediatric Drugs, 2006Co-Authors: James E. Frampton, Susan J. KeamAbstract:▲ Boostrix® US formulation (hereafter referred to as Tdap) is a formulation of reduced-antigen, combined diphtheria-tetanus-acellular Pertussis Vaccine, adsorbed onto aluminium approved in the US for use as a single-dose booster immunization in adolescents aged 10–18 years. ▲ The diphtheria and tetanus toxoid components of Tdap elicited serologic immune responses comparable to those induced by an approved diphtheria-tetanus (Td) booster Vaccine in a large (n = 4114), randomized, observer-blind, multicenter, pivotal trial in US adolescents aged 10–18 years. ▲ In addition, antibody levels against Pertussis antigens (Pertussis toxoid, filamentous hemagglutinin, and pertactin) induced by Tdap were non-inferior to, and numerically higher than, those induced in infants who completed a three-dose primary immunization course with combined diphtheria-tetanus-acellular Pertussis Vaccine (Infanrix®), which conferred 89% protection against Pertussis. ▲ Tdap had a similar reactogenicity profile, including solicited local reactions and general symptoms, to that of the approved Td Vaccine in the pivotal US study. In particular, Tdap was similar (non-inferior) to Td with respect to the primary safety endpoint, namely the incidence of grade 3 pain at the injection site within the 15-day post-vaccination period. ▲ No serious adverse events of potential autoimmune origin or of a new-onset, chronic nature were reported during the 6-month post-vaccination period in the pivotal US study and a smaller (n = 319) German-based trial that also evaluated Tdap.
Helen E. Quinn - One of the best experts on this subject based on the ideXlab platform.
-
pregnant women s intention to take up a post partum Pertussis Vaccine and their willingness to take up the Vaccine while pregnant a cross sectional survey
Vaccine, 2013Co-Authors: Kerrie E Wiley, Helen E. Quinn, Peter D Massey, Spring Chenoa Cooper, Nicholas Wood, Julie LeaskAbstract:Abstract Introduction Post-partum vaccination of new mothers is currently recommended in Australia to reduce Pertussis infection in infants. Internationally, vaccination recommendations now include pregnant women in some countries. Understanding the awareness of Pertussis vaccination recommendations among pregnant women, and their willingness to have the Vaccine while pregnant is important for informing Vaccine program implementation. Objective To determine awareness and intentions toward current recommendations for post-partum Pertussis vaccination among Australian pregnant women, and their willingness to accept Pertussis Vaccine during pregnancy, should it be recommended in Australia in the future. Design Quantitative self-administered survey, using a non-random stratified sampling plan based on representative proportions by age, parity and region of residence. Participants and setting Pregnant women receiving antenatal care through three large, demographically diverse referral hospitals in metropolitan, urban and rural New South Wales, Australia. Results The response rate was 815/939 (87%). Most women (80%) reported willingness to have the Pertussis Vaccine during pregnancy, should it be recommended. Thirty four per cent of women intended to receive a Pertussis Vaccine post-partum, 17% had received it previously, while 45% had never heard of Pertussis Vaccine, had not thought about it, or were undecided about having it. Compared with those who had not received a recommendation to have the Vaccine post-partum, women who had received a recommendation were 7 times more likely (95% CI 4–14) to report intention to have the Vaccine. Conclusions Health care provider recommendation is paramount to raising awareness of Pertussis vaccination recommendations among pregnant women. Women's willingness to have the Vaccine while pregnant is encouraging, and indicates the potential for high Pertussis Vaccine coverage among pregnant women, should it be recommended in Australia.
-
Pertussis Vaccine effectiveness after mass immunization of high school students in Australia.
The Pediatric infectious disease journal, 2009Co-Authors: Claudia Rank, Helen E. Quinn, Peter McintyreAbstract:Vaccine effectiveness in the first large-scale use of adolescent Pertussis Vaccine in Australia was evaluated by the screening method. Vaccine effectiveness was 78.0% (95% CI: 60.7-87.6%) for all study cases (n = 167), increasing to 85.4% (95% CI: 83.0-87.5%) for laboratory-confirmed cases (n = 155). Effectiveness should be comparable in settings with similar programs, such as the United States and Canada.
James E. Frampton - One of the best experts on this subject based on the ideXlab platform.
-
Reduced-Antigen, Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine, Adsorbed (Boostrix® US Formulation)
Pediatric Drugs, 2006Co-Authors: James E. Frampton, Susan J. KeamAbstract:▲ Boostrix® US formulation (hereafter referred to as Tdap) is a formulation of reduced-antigen, combined diphtheria-tetanus-acellular Pertussis Vaccine, adsorbed onto aluminium approved in the US for use as a single-dose booster immunization in adolescents aged 10–18 years. ▲ The diphtheria and tetanus toxoid components of Tdap elicited serologic immune responses comparable to those induced by an approved diphtheria-tetanus (Td) booster Vaccine in a large (n = 4114), randomized, observer-blind, multicenter, pivotal trial in US adolescents aged 10–18 years. ▲ In addition, antibody levels against Pertussis antigens (Pertussis toxoid, filamentous hemagglutinin, and pertactin) induced by Tdap were non-inferior to, and numerically higher than, those induced in infants who completed a three-dose primary immunization course with combined diphtheria-tetanus-acellular Pertussis Vaccine (Infanrix®), which conferred 89% protection against Pertussis. ▲ Tdap had a similar reactogenicity profile, including solicited local reactions and general symptoms, to that of the approved Td Vaccine in the pivotal US study. In particular, Tdap was similar (non-inferior) to Td with respect to the primary safety endpoint, namely the incidence of grade 3 pain at the injection site within the 15-day post-vaccination period. ▲ No serious adverse events of potential autoimmune origin or of a new-onset, chronic nature were reported during the 6-month post-vaccination period in the pivotal US study and a smaller (n = 319) German-based trial that also evaluated Tdap.